Technology Bundle ID
TAB-3013

Alloreactive T Cell Depletion Method For Preventing Graft-Versus-Host Disease

Linked ID
E-125-2015-0
Lead Inventors
Dhanalakshmi Chinnasamy (NHLBI)
Co-Inventors
Gregory Whitehill (NHLBI)
John Barrett (NHLBI)
Development Stages
Discovery
Development Status
Early-stage
ICs
NHLBI
The invention relates to the use of adenosine to deplete alloreactive T cells from donor grafts to prevent graft-versus-host disease (GVHD). The method includes culturing donor cells that include T cells with recipient antigen presenting cells (APCs) to form a mixture of cells. The recipient’s APCs activate donor T cells. The activated T cells are treated with high doses of adenosine or an adenosine-like molecule to decrease or inhibit viability of the activated donor T-cells. The adenosine or adenosine-like molecule is filtered away from the mixture resulting in cells that can be transplanted into the recipient.
Commercial Applications
  • Transplantation rejection prevention
  • Graft-versus-Host disease
Competitive Advantages
  • T cell selective
  • Non invasive

Request More Info

Licensing Contact: